Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom

finance.yahoo.com · 2026-08-28

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]

TickrTrends take: Edwards Lifesciences maintains a position as a significant player in the transcatheter aortic valve replacement market, a sector experiencing sustained demand growth. Given TickrTrends' undervalued assessment, investors monitoring Healthcare valuations may want to track whether the company's TAVR-focused business model continues to justify its current market price relative to growth and profitability metrics. The dominance in this specialized medical device category represents a key factor in evaluating whether the valuation gap persists or narrows over time.

Read the full story at finance.yahoo.com →